Advances in Alzheimer's Disease

Advances in Alzheimer's Disease

ISSN Print: 2169-2459
ISSN Online: 2169-2467
www.scirp.org/journal/aad
E-mail: aad@scirp.org
"Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial"
written by Timothy Nicholas, Sridhar Duvvuri, Claire Leurent, David Raunig, Tracey Rapp, Phil Iredale, Carolyn Rowinski, Robert Carr, Patrick Roberts, Athan Spiros, Hugo Geerts,
published by Advances in Alzheimer's Disease, Vol.2 No.3, 2013
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Conceptual and organizational barriers to quantitative systems pharmacology modeling of pathophysiological systemic drug hypotheses
CPT: Pharmacometrics & Systems …, 2022
[2] Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
Frontiers in neuroscience, 2021
[3] Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the …
2021
[4] Synthèse de ligands iodés et fluorés en série indazole: application en imagerie des récepteurs 5-HT4 centraux
2020
[5] Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data
2020
[6] Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
2020
[7] Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)
2020
[8] Simulating the Effects of Common Comedications and Genotypes on Alzheimer's Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach
2020
[9] Salvaging CNS Clinical Trials Halted Due to COVID‐19
2020
[10] A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19
2020
[11] Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
2019
[12] Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D
2019
[13] Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model
2018
[14] Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases
Expert Review of Clinical Pharmacology, 2018
[15] Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
Journal of Psychopharmacology, 2018
[16] Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment
2017
[17] Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's Disease
European Journal of Pharmacology, 2017
[18] Knowledge-driven computational modeling in Alzheimer's research: Current state and future trends
Alzheimer's & Dementia, 2017
[19] Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop
European Neuropsychopharmacology, 2017
[20] Knowledge-driven computational modeling in Alzheimer's disease research: Current state and future trends
2017
[21] Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge
Alzheimer's & Dementia, 2016
[22] The promises of quantitative systems pharmacology modelling for drug development
Computational and Structural Biotechnology Journal, 2016
[23] From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge
Alzheimer's & Dementia, 2016
[24] Big data to smart data in AD: Real-world examples of advanced modeling and simulation
Alzheimer's & Dementia, 2016
[25] A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
Frontiers in pharmacology, 2016
[26] Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
Frontiers in pharmacology, 2015
[27] Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
Future medicinal chemistry, 2015
[28] Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient …
Frontiers in Pharmacology, 2015
[29] SF 424 (R&R) APPLICATION FOR FEDERAL ASSISTANCE Page 2
2015
[30] A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition …
Frontiers in pharmacology, 2014
[31] Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward
Future medicinal chemistry, 2014
[32] A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
Frontiers in pharmacology, 2014
[33] Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient …
Frontiers in Pharmacology, 2014
[34] Virtual Twin Patients Can Bridge Data Gaps for COVID-19 Halted Clinical Trials
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top